Summer Road Amends Ocular Therapeutix Stake Disclosure

TL;DR

**Summer Road LLC just updated their 13D on Ocular Therapeutix, signaling a change in their stake or intentions.**

AI Summary

Summer Road LLC filed an Amendment No. 5 to its Schedule 13D on February 27, 2024, regarding its beneficial ownership in Ocular Therapeutix, Inc. The event requiring this filing occurred on February 26, 2024. This amendment updates previous disclosures concerning their holdings of Ocular Therapeutix's Common Stock, which has a par value of $0.0001 per share.

Why It Matters

This filing indicates an update to a significant shareholder's position or intentions regarding Ocular Therapeutix, which could signal changes in corporate governance or future strategic moves.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often signal changes in a significant shareholder's position or intent, which can influence stock price or corporate control.

Key Numbers

• Amendment No. 5 — Amendment Number (Indicates multiple prior filings)
• February 26, 2024 — Date of Event (Triggered the filing)

Key Players & Entities

• OCULAR THERAPEUTIX, INC. (company) — Issuer
• SUMMER ROAD LLC (company) — Filing Person
• Frank S. Vellucci, Esq. (person) — Contact for Notices
• Norton Rose Fulbright US LLP (company) — Legal Counsel
• $0.0001 (dollar_amount) — Par Value Per Share

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securitie
• $7.52 — ,851 shares of Common Stock at price of $7.52 per share (collectively, the " Purchase
• $6,999,999.52 — o. 001-36554). A total of approximately $6,999,999.52 was paid to purchase the Purchased Shar

Filing Documents

• ef20022344_sc13da.htm (SC 13D/A) — 63KB
• 0001140361-24-009774.txt ( ) — 64KB

is hereby amended as follows

Item 3 is hereby amended as follows: On February 26, 2024, as part of a private placement offering (the " Private Placement Offering "), the Reporting Person purchased 930,851 shares of Common Stock at price of $7.52 per share (collectively, the " Purchased Shares ") pursuant to the terms of a securities purchase agreement, as described in the Issuer's Form 8-K filed with the Securities and Exchange Commission (the " SEC ") on February 22, 2024 (File No. 001-36554). A total of approximately $6,999,999.52 was paid to purchase the Purchased Shares. The Reporting Person used available cash to pay for the Purchased Shares, and it did not borrow any funds for the purchase of any of the Purchased Shares. In connection with the Private Placement Offering, the Reporting Person, as well as the other investors that participated in the Private Placement Offering (the " Investors "), additionally entered into a registration rights agreement (the " Registration Rights Agreement ") with the Issuer, pursuant to which the Issuer agreed to file a registration statement covering the resale by the Investors of their respective securities acquired in connection with the Private Placement Offering, including the Purchased Shares (collectively, the " Registrable Securities "), no later than 30 days following the closing of the Private Placement Offering. The Issuer has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Registrable Securities. Item 4. Purpose of Transaction . The transaction described in this Amendment No. 5 was made for investment purposes. The Reporting Person does not have any plans or proposals which would result in any of the following: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A

View Full Filing

View this SC 13D/A filing on SEC EDGAR